Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type2diabetes
Phase EARLY_PHASE1
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The majority of T2DM adults show thiamine (vitamin B1) deficiency which may contribute to impaired function. This study will examine patients with T2DM through brain MRI scans, cognition assessments, blood tests, and questionnaires. Our goal is to see if a thiamine treatment (taking vitamin B1 capsules) can improve function. Patients will be asked to come to UCLA two times three months apart and each visit will last about 2.5-3 hours.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Dietary Supplement: Thiamine — Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.
  • Other: Placebo — Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.

Primary Outcomes

  • Assess if BBB function has been repaired. (After 3 months)
  • Analyze blood serum S100β levels. (After 3 months)
  • Examine cognition in T2DM adults with thiamine treatment. (After 3 months)
  • Cognition assessment in T2DM adults after thiamine treatment. (After 3 months)
  • Examine depression in T2DM adults with thiamine treatment. (After 3 months)
  • Assess anxiety in T2DM adults with thiamine treatment. (After 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-08-01
Completion: 2027-03-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Collaborators: National Institute on Aging (NIA)
Contact Information
Study Contact:
Rajesh Kumar, PhD
310-206-1699
rkumar@mednet.ucla.edu
Dineth R Karunamuni, MS
856-701-5332
dkarunamuni@mednet.ucla.edu
Rajesh Kumar, PHD
310-825-1808
rkumar@mednet.ucla.edu
UCLA
Interventions
  • Dietary Supplement: Thiamine — Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.
  • Other: Placebo — Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.
Study Locations (1 sites)
UCLA, Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed T2DM * Outpatient status * Able to lay flat for imaging Exclusion Criteria: * A previous history of stroke * Current in-take of thiamine * Known thiamine allergy * Seizure disorder * Head trauma * Myocardial infarction * Current pregnancy (if female) * Diagnosed neuropsychiatric disorders (clinical depression, schizophrenia, manic-depression) * Diagnosed dementia * Sleep disordered breathing * Airway or chest deformities that would interfere with breathing * Chronic obstructive pulmonary disease * Cystic fibrosis * Presence of brain mass lesions * Any history of drug abuse (e.g., cocaine, tobacco, or cannabis) * Renal failure (requiring dialysis) * All T2DM adults with metallic and electronic implants (phrenic or cardiac pacemakers; although some pacemakers and cardioverter defibrillators are safe at a low magnetic field, they are not safe at 3.0-Tesla scanner) * Non-removable insulin pump/glucose sensor * Braces * Body weight more than 300 pounds (weight and height will be used to calculate BMI to determine if the patient will fit in the scanner and stay within parameters of size restrictions of MRI scanner table) * Any other contraindications to MRI, such as claustrophobia, or metallic-based tattoos, as per MRI safety website suggestions, will also be excluded.
Conditions Unipolar Depression, Bipolar Disorder
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Intermittent and continuous theta-burst stimulation (iTBS and cTBS respectively) are the newer modalities of transcranial magnetic stimulation with documented efficacy in treatment of depressed mood but with conflicting results regarding their efficacy in treatment of other symptoms of depression such as insomnia, daytime sleepiness and fatigue. This study will investigate the efficacy of iTBS over the left dorsolateral prefrontal cortex (DLPFC) and cTBS over the right DLPFC, compared to sham stimulation, in treatment of insomnia, daytime sleepiness and fatigue in depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: iTBS — Active iTBS over the left DLPFC to induce the long term potentiation of stimulated area.
  • Device: cTBS — Active cTBS over the right DLPFC to induce the long term potentiation of stimulated area.
  • Device: Sham — Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.

Primary Outcomes

  • Beck Depression Inventory 2 (Before intervention - four weeks after finishing intervention.)
  • Pittsburgh Sleep Quality Index (Before intervention - four weeks after finishing intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-15
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jakub Antczak
Collaborators: Institute of Psychiatry and Neurology, Warsaw
Principal Investigators:
  • Bogdan Stefanowski, MD (PRINCIPAL_INVESTIGATOR) - Institute of Psychiatry and Neurology
Contact Information
Study Contact:
Bogdan Stefanowski, MD
+48 22 45 82 532
bstefanowski@ipin.edu.pl
Jakub Antczak, MD
+48 12 400 25 50
jakub.antczak@uj.edu.pl
Bogdan Stefanowski
+48 22 45 82 532
bstefanowski@ipin.edu.pl
Institute of Psychiatry and Neurology
Interventions
  • Device: iTBS — Active iTBS over the left DLPFC to induce the long term potentiation of stimulated area.
  • Device: cTBS — Active cTBS over the right DLPFC to induce the long term potentiation of stimulated area.
  • Device: Sham — Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.
Study Locations (1 sites)
Institute of Psychiatry and Neurology, Warsaw, 02957 Poland
Eligibility Criteria
Inclusion Criteria: * severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion * Diagnosis of major depression (F33.1 or F33.2) or bipolar disorder (F31.3 or F31.4). * The score of the Athens Insomnia Scale five or more * Unchanged antidepressive pharmacotherapy at least one month prior to inclusion Exclusion Criteria: * Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy * Psychotic symptoms at the time of inclusion * Suicidal ideations and/or attempts within three months prior to inclusion

Asthma Link Effectiveness Trial

NCT06388460
Recruiting
Conditions Childhood Asthma
Phase NA
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this cluster Randomized Control Trial is to determine the effectiveness of Asthma Link, a school supervised asthma therapy program, compared with an educational asthma workbook, in improving asthma symptoms for children with poorly controlled asthma aged 5-14.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Asthma Link — Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
  • Other: Enhanced Usual Care — Providers enroll patients to receive an asthma educational workbook

Primary Outcomes

  • Improving Asthma Symptoms (Baseline, 6 months, 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-04
Completion: 2028-04
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Collaborators: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Michelle Trivedi, MD (PRINCIPAL_INVESTIGATOR) - UMass Chan Medical School
Contact Information
Study Contact:
Michelle Trivedi, MD
7744418086
Michelle.Trivedi3@umassmed.edu
Michelle Spano, MA
17746966875
michelle.spano@umassmed.edu
Michelle Spano
5088562990
michelle.spano@umassmed.edu
University of Massachusetts Chan Medical School
Interventions
  • Other: Asthma Link — Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
  • Other: Enhanced Usual Care — Providers enroll patients to receive an asthma educational workbook
Study Locations (1 sites)
University of Massachusetts Chan Medical School, Worcester, Massachusetts 01655 United States
Eligibility Criteria
STUDY INCLUSION/EXCLUSION CRITERIA: Child Inclusion Criteria: * Meet the eligibility criteria for Asthma Link (as described below) * Enrolled in Asthma Link (if randomized to the Asthma Link Condition) * Able and willing to provide informed assent Child Exclusion Criteria: * Unable or unwilling to provide informed assent * Developmental delay that would prevent study participation. Parent Inclusion Criteria: * Parent/guardian to patient * 18 years or older * Able to understand and communicate in English or Spanish * Able and willing to provide informed consent. Child eligibility for children enrolled in Asthma Link: * children aged 5-14 years (enrolled in grade K-8) * prescribed daily inhaled corticosteroid (ICS) for asthma * Asthma Control Test (ACT) score ≤19 OR 1 or more of ANY of following in the past 1 year: course of oral steroids, hospitalization, Emergency Department visit, sick visit for asthma * parent/child report of poor ICS adherence on adherence checklist- i.e. child or parent says "Yes" when provider asks if they have difficulty remembering to take their medication or if they regularly take medication holidays or breaks * able and willing to assent * parental permission * English or Spanish speaking
Conditions Diabetes Mellitus, Type 2, Food Insecuri...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study seeks to address the multifaceted challenges posed by food disparities and their negative consequences on health outcomes, via a comprehensive community health intervention program. Study objectives include: 1. To describe the social-demographic and clinical factors associated with food insecurity in the hospitalized diabetic population. 2. To design, implement and evaluate a nutrition program targeting the hospitalized diabetic population. The investigators will prospectively randomize the target population into either a nutrition program (Intervention), or state-of-art standard of care (SOC) in a 4:1 ratio. Participants in the intervention group will be provided the following two resources in addition to SOC: 1) Enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge) 2) Education at discharge and continuing outreach to enhance knowledge for better diet and food options. 3. To enhance community engagement and develop a systematic implementation plan for long-term roll-out of the nutrition program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Nutrition program — Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.

Primary Outcomes

  • Food insecurity at 60 -days post initial discharge (60 days from discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-07
Completion: 2027-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Neera Ahuja, MD (PRINCIPAL_INVESTIGATOR) - Stanford University
  • Christine Santiago, MD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Christine Santiago, MD
(650) 725-5071
csantia2@stanford.edu
Neera Ahuja, MD
650-725-3515
nahuja@stanfordhealthcare.org
Stanford Medicine
Interventions
  • Other: Nutrition program — Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
Study Locations (1 sites)
Stanford Medicine, Palo Alto, California 94304 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Type 1 or Type 2 Diabetes Mellitus * Admitted to Stanford Healthcare inpatient unit * Residence in California at time of enrollment * Positive Screening for Food Insecurity * On a Healthcare Plan covered by Mom's Meals. Exclusion Criteria: * Plans to be discharged to a skilled nursing facility. * Patients who prefer a language for which a short-form consent is not available. * No Home Address * Pregnant Participants. * No access to refrigerator.
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational and prospective study is to investigate changes in physical performance, lung function, respiratory and peripheral muscle strength in patients during the postoperative period following pulmonary endarterectomy (PET).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • To investigate changes in physical performance measured by Six-Minute Walk Test. (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery.)
  • To investigate changes in physical performance measured by Short Physical Performance Battery (SPPB). (Baseline (one day before the surgery), after the surgery (the day immediately after ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after surgery.)
  • To investigate changes in physical performance by 1-minute sit-to-stand test (1-MSTST). (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate changes in peripheral muscle strength. (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate changes in respiratory muscle strength: (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate changes in lung function test measure by spirometry: (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
  • To investigate frailty by Clinical Frailty Scale (CFS) (Baseline (one day before the surgery), after the surgery (the day immediately ICU discharge), before the hospital discharge (an average of 20 days) and 6 months after the surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-29
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Principal Investigators:
  • Rafael M Ianotti, PT (PRINCIPAL_INVESTIGATOR) - Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Contact Information
Study Contact:
Rafael M Ianotti, PT
+55 11 26615319
rafael.ianotti@hc.fm.usp.br
Orival Freitas Filho, MD
Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Fabio B Jatene, MD,PhD
Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Interventions
N/A
Study Locations (1 sites)
Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo 05403-000 Brazil
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Both genders * Elective pulmonary endarterectomy surgery * Absence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the preoperative period. Exclusion Criteria: * Reoperation for any reason * Presence of cognitive or peripheral motor impairment that prevents the performance of functional tests in the postoperative period.
Conditions Pulmonary Hypertension, Chronic Kidney D...
Phase Not Applicable
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to examine the association between urinary and plasma biomarkers and change in estimated glomerular filtration rate (eGFR) among patients with pulmonary hypertension (PH).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention is planned as part of the study — No intervention is planned as part of the study

Primary Outcomes

  • Major adverse kidney events (Baseline to 12 months)
  • Worsening PH or HF (Baseline to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-31
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Giessen
Collaborators: Icahn School of Medicine at Mount Sinai, University of Virginia, Kerckhoff Klinik, Universitätsklinikum Hamburg-Eppendorf
Principal Investigators:
  • Faeq Husain-Syed, MD (PRINCIPAL_INVESTIGATOR) - University of Giessen
Contact Information
Study Contact:
Faeq Husain-Syed, MD
+49 641 985 42378
faeq.husain-syed@innere.med.uni-giessen.de
Birgit Jennert, MLA
+49 641 985 42378
birgit.jennert@innere.med.uni-giessen.de
Faeq Husain-Syed, MD
+49 641 985 42378
faeq.husain-syed@innere.med.uni-giessen.de
University Hospital Giessen and Marburg, Campus Giessen, Department of Internal Medicine II
Interventions
  • Other: No intervention is planned as part of the study — No intervention is planned as part of the study
Study Locations (2 sites)
Kerckhoff Klinik Heart and Thorax Center, Bad Nauheim, Hesse Germany
University Hospital Giessen and Marburg, Campus Giessen, Department of Internal Medicine II, Giessen, Hesse 35392 Germany
Eligibility Criteria
Inclusion Criteria: * Inpatients aged ≥18 years * Undergoing right heart catheterization (RHC) Exclusion Criteria: * multifactorial or indeterminate PH, for which no single underlying mechanism could be reliably classified * active tumor disease requiring targeted therapy * inflammatory or autoimmune disease with renal involvement requiring systemic immunosuppressive treatment * unexplained kidney function decline, defined as serum creatinine increase ≥0.5 mg/dL from baseline within the prior 7 days before RHC * Chronic kidney disease with eGFR \<20 ml/min/1.73 m2 * non-kidney failure requiring extracorporeal or peritoneal ultrafiltration for diuretic-resistant volume overload * if they had received non-steroidal anti-inflammatory drugs or intravenous contrast within 72 hours before RHC * prediagnosed glomerulonephritis * polycystic kidney disease * postrenal obstruction * single kidney (functional or anatomical) * solid organ transplantation * anticipated life expectancy of \<12 months * likelihood of receiving advanced therapy (mechanical circulatory assist device/lung or cardiac transplant) * pregnancy or possibility of pregnancy in the next 12 months * inability to cooperate with respiratory maneuvers during renal Doppler * refusal to participate * not available for follow-up visits

The Man Van Project

NCT06357416
Recruiting
Conditions Prostate Cancer, Urologic Cancer, Urolog...
Phase NA
Enrollment 4000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care at the site of their work and in their communities. The initial focus of this new standard of care clinic is to access workplaces with large manual workforces where large scale working from home is not possible. These will include logistics firms and bus companies. These companies employ large numbers of black and minority ethnic men who also have poorer outcomes with a range of other diseases, including Coronavirus disease (COVID)-19. The novel clinical service will collaborate with Unite (and other unions) as well as employers in order to reach our target groups effectively. There is also the opportunity to target higher risk groups e.g. Afro Caribbean communities whose rates of prostate cancer are 1 in 41 as well as occupational higher risk categories. The Man Van has the potential to swing the balance of evidence in favour of Prostate-Specific Antigen (PSA) screening, with a targeted screening program directed at high-risk groups including ethnic minorities and manual workers. Reasons for poorer outcomes amongst these groups are multi-factorial and complex. Levels of education are often a factor which can impact the understanding of the disease and how to seek assistance. Distrust of medical organisations has also been cited as a factor. The aim of the Man Van mobile outreach service is to enable men access to a specific men's health service - focusing on general health and wellbeing (including BMI assessment, blood pressure, blood sugar/diabetes checks etc) and a prostate check for those who raise concerns. This will include a PSA test where relevant. This will be the core data gathered from the project. Patients will receive PSA results in the 'Man Van' by a clinical nurse specialist with patients with raised PSA levels being referred into the standard rapid referral cancer pathways. Similar considerations will apply to men with haematuria detected on dip stick testing or who present with a testicular mass or penile lesion (both rare but important). The clinical data generated from each routine health screening appointment will be analysed to determine the effectiveness of the Man Van mobile outreach model in identifying prostate and other male cancers and other co-morbidities much earlier than if patients had waited to present to their General Practitioner (GP) or other healthcare provider. Patients who receive an early diagnosis of clinically significant prostate cancer will have access to early curative treatments, which are typically less invasive and shorter in timescales. Similar interventions have shown large scale success in particular with breast and cervical cancer. The NHS sees many patients accessing cancer care at a late stage. Reducing this trend is a key objective of the NHS Long Term Plan. The…

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: MV-POCT Sub-study — Point of care blood testing
  • Other: Main Man Van Group Sub-study (MV-Eco) — Consent for long-term follow-up of patients
  • Other: MV-QualQ Sub-study — Qualitative questionnaire and interview sub-study
  • Diagnostic Test: MV-PRS Sub-study — Patients consenting to polygenic risk score testing
  • Other: MV-DNA and MV-UctDNA Sub-study — Patients consenting to collection of DNA and urine for further study.
  • Other: Man Van patients — All patients seen in Man Van
  • Other: MV-SSI Sub-study — Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.
  • Other: MV-TPP Sub-study — Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.

Primary Outcomes

  • Cancer detection rates (1 year)
  • Detection rates of other diseases (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-13
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: true
Enrollment: 4000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal Marsden NHS Foundation Trust
Collaborators: RM Partners West London Cancer Alliance, Institute of Cancer Research, United Kingdom, Imperial College London
Principal Investigators:
  • Nicholas D James, MBBS, FRCP, FRCR, PhD (PRINCIPAL_INVESTIGATOR) - Institute of Cancer Research/Royal Marsden NHS Trust
Contact Information
Study Contact:
Nicholas D James, MBBS, FRCP, FRCR, PhD
02071535130
nick.james@icr.ac.uk
Masood R Moghul, MBBS, FRCS (Urol)
02071535130
masood.moghul@rmh.nhs.uk
Ann Gandolfi
02086613903
ann.gandolfi@rmh.nhs.uk
Royal Marsden Hospital NHS Foundation Trust
Interventions
  • Device: MV-POCT Sub-study — Point of care blood testing
  • Other: Main Man Van Group Sub-study (MV-Eco) — Consent for long-term follow-up of patients
  • Other: MV-QualQ Sub-study — Qualitative questionnaire and interview sub-study
  • Diagnostic Test: MV-PRS Sub-study — Patients consenting to polygenic risk score testing
  • Other: MV-DNA and MV-UctDNA Sub-study — Patients consenting to collection of DNA and urine for further study.
Study Locations (1 sites)
Royal Marsden Hospital NHS Foundation Trust, London, SW3 6JJ United Kingdom
Eligibility Criteria
Patients are eligible to be included in the research study if they are eligible to access the Man Van mobile outreach clinic, which is a novel clinical service delivered by The Royal Marsden Hospital NHS Foundation Trust. The inclusion and exclusion criteria have been designed to be as broad as possible, in order to include data from as many patients using the Man Van clinical service as possible. As the primary purpose of the Man Van mobile outreach clinic is to screen for prostate, testicular, penile and other cancers that affect men, only men are eligible to be reviewed in the mobile outreach clinic hence only males will be recruited into this study. Inclusion criteria for the Main Study 1. Participating in the linked Man Van mobile outreach clinic 2. Age ≥45 years 3. Male (The initial pilot study had a age criteria of ≥18 years, but this was amended). MV-POCT Inclusion Criteria: Any patient having a PSA and/or an HbA1c test as part of a Man Van work up, or via the our rapid diagnostics clinic. MV-QualQ Inclusion Criteria: Any patient attending the Man Van for an assessment. MV-Eco Inclusion Criteria: Any patient attending the Man Van for an assessment. MV-PRS Inclusion Criteria: Any patient attending the Man Van for an assessment and able to provide saliva samples. MV-DNA Inclusion Criteria: Any patient attending the Man Van for an assessment, and able to provide blood/saliva samples. MV MV-UctDNA Inclusion Criteria: Any patient attending the Man Van for an assessment, and able to provide urine samples. MV-SSI Inclusion criteria: * Aged \> 18 and over (on date of invitation to participate) * Works for healthcare organisation, other stakeholder or professional or potential man van patient who was not seen or relative of a Man Van patient/potential patient Exclusion criteria: * Man van patient who has attended appointment MV-TPP Inclusion criteria: Healthcare Professionals * Aged \> 18 and over (on date of invitation to participate) * Speaks English * Works within the UK * Profession: GPs, Practice Staff (Nurses, Physician Assistants and Associates * Healthcare assistants) * Experienced in adopting new tests and guidelines into practice. * Experienced in detecting, managing, and referring symptoms and asymptomatic patients with symptoms of prostate, pancreatic, GI cancer and/or are at an increased risk of developing these cancers. Patients * Aged \> 18 and over (on date of invitation to participate) * Speaks English * Lives in the UK * Patients with direct and in-direct experience with prostate, pancreatic, GI cancers. * Patients at an increased risk of developing prostate, pancreatic, GI cancer in accordance with known risk factors, which includes age, smoking, being overweight or obese, family history and genetic factors, pancreatitis, and diabetes. Other key stakeholders/professionals • Aged \> 18 and over (on date of invitation to participate) • Speak English * Works within the UK * Professions: medical devices and biomedical researchers, scientists, representatives for major regulatory and funding bodies * Knowledgeable of Early Detection initiatives (tests, outreach programes) Exclusion criteria: GPs • Individuals who are unwilling to take part in the study. * Individuals with no experience in adopting new cancer tests and guidelines into practice. * Individuals with no experience in in detecting, managing, and referring patients with symptoms of cancer and/or are at an increased risk of developing prostate, pancreatic, GI cancer. * Individuals who do not adequately understand verbal explanations or written information in English. Patients • Individuals who are unwilling to take part in the study. • Individuals who do not adequately understand verbal explanations or written information in English. • Unable to provide written and verbal consent. • No direct or indirect lived experience with prostate, pancreatic, GI cancers. Non-clinical key stakeholders/professionals • Individuals who are unwilling to take part in the study • Individuals who are not familiar with cancer biomarkers and medical tests • Individuals with no knowledge of early detection • Individuals who do not adequately understand verbal explanations or written information in English
Conditions Anatomic Stage 0 Breast Cancer AJCC v8, ...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial evaluates manual lymphatic drainage breast massage for reducing treatment-related side effects in women undergoing radiation therapy after breast conserving surgery for breast cancer that has not spread to other parts of the body (localized). Breast conserving surgery can be an effective treatment option for early stage breast cancer, but it can also be associated with side effects including fluid collection in tissues/swelling (lymphedema), pain, reduced quality of life, and poorer body image. Manual lymphatic drainage is a gentle massage technique used to reduce swelling. It may be a safe and effective way to reduce treatment-related side effects in women receiving radiation therapy after surgery for localized breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Lymphedema Management — Undergo MLD breast massage
  • Other: Questionnaire Administration — Ancillary studies
  • Radiation: Adjuvant breast radiation therapy — Using standard 3D conformal or intensity modulated techniques, patients will receive standard fractionation or moderate hypofractionation radiation therapy. The radiation treatment will last for 3 to 6 weeks, with the length of treatment depending on patient's specific clinical situation.

Primary Outcomes

  • Rate of compliance of MLD breast massage sessions (Up to 1 month after completion of radiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-24
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • May L Tao, MD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Kimberly Arieli, RN
323-865-0451
Kimberly.Arieli@med.usc.edu
Kimberly Arieli, RN
323-865-0451
Kimberly.Arieli@med.usc.edu
USC / Norris Comprehensive Cancer Center
May L. Tao, MD
USC / Norris Comprehensive Cancer Center
Interventions
  • Other: Lymphedema Management — Undergo MLD breast massage
  • Other: Questionnaire Administration — Ancillary studies
  • Radiation: Adjuvant breast radiation therapy — Using standard 3D conformal or intensity modulated techniques, patients will receive standard fractionation or moderate hypofractionation radiation therapy. The radiation treatment will last for 3 to 6 weeks, with the length of treatment depending on patient's specific clinical situation.
Study Locations (1 sites)
USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Eligibility Criteria
Inclusion Criteria: * Female with native breasts and localized breast cancer who are status post-lumpectomy surgery, will receive whole breast radiation therapy with/without nodal irradiation, with standard fractionation or moderate hypofractionation * Age \>= 18 years * Ability to understand and the willingness to sign a written informed consent in English or Spanish Exclusion Criteria: * Underlying diagnosis of chronic inflammatory illness or collagen vascular disorder, e.g. scleroderma, lupus, rheumatoid arthritis, fibromyalgia as these conditions may significantly affect the likelihood and magnitude of radiation related toxicity * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Inability to provide written informed consent in English or Spanish * Patients receiving ultra-hypofractionation, and/or partial breast or chest wall radiation therapy are excluded
Conditions Obstructive Sleep Apnea, Asthma
Phase NA
Enrollment 138
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to evaluate the impact of CPAP treatment on asthma control in patients with severe uncontrolled asthma and obstructive sleep apnea (OSA)

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: CPAP treatment — Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
  • Other: Hygienic and dietary advice — Subjects allocated to this arm will receive hygienic and dietary counselling

Primary Outcomes

  • Asthma control questionnaire (12 months)
  • Asthma control test (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-29
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Clinic of Barcelona
Principal Investigators:
  • Mireia Dalmases, MD (PRINCIPAL_INVESTIGATOR) - Hospital Clinic
Contact Information
Study Contact:
Mireia Dalmases, MD
+34932275746
mdalmase@clinic.cat
Interventions
  • Device: CPAP treatment — Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
  • Other: Hygienic and dietary advice — Subjects allocated to this arm will receive hygienic and dietary counselling
Study Locations (1 sites)
Hospital Clinic Barcelona, Barcelona, Spain 08036 Spain
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * Diagnosis of severe uncontrolled asthma according to the criteria of the Spanish Asthma Management Guide (GEMA) or the Global Initiative for Asthma (GINA) and no hospitalizations the month prior to inclusion in the study. * Apnea hypopnea rate greater than or equal to 15/hour * Punctuation in the Epworth Sleepiness Scale ≤10 * Obtaining informed consent. Exclusion Criteria: * Previous treatment with CPAP * Patient with central sleep apnea or Cheyne-Stokes respiration * Other sleep disorders: narcolepsy, restless leg syndrome, chronic insomnia, * Resistant hypertension * Active Smoking * Unstable comorbidities or medications may interfere with asthma control * Pregnancy * Any process that reduces life expectancy to \<1 year, * Any medical or social factor that may limit CPAP compliance
Conditions Hypertension, Diabetes Mellitus Type 2, ...
Phase NA
Enrollment 2560
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this cluster randomized trial is to evaluate the effectiveness of the RISIMA model based on an integrated county healthcare consortium implemented by multi-level family health teams (FHTs)on patients with diabetes and/or hypertension, including CVD risk assessment, treatment, and management.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Team-based care — The RISIMA model is provided by a family healthcare team composed of one village doctor, one general physician at township health centers and one specialist including cardiologists, neurologists or endocrinologists from county hospital. For villages without village doctor, public health professionals from township health centers would join the service team as the supplement. Within the team, three team members carry the different function. Village doctor is responsible for regular home visits, CVD risk measurement and organizing health education course. GP as the core service provider in the team is responsible for CVD risk monitoring, providing health education course for middle-high risk participants, and generating integrated care plans for each participant. Specialist is responsible for providing guidance particularly for high-risk population management to township and village doctors within the team.
  • Procedure: Risk-stratified care pathway — Based on WHO/ISH score, baseline population will be divided into three groups-low risk (10-year CVD risk: \&lt;10%), middle risk (10-year CVD risk: 10%\~20%) and high risk (10-year risk: \&gt;20%). With the support from experts and health care professionals, study had developed a risk-stratified care pathway on the basis of clinical guidance. According to the pathway, participants at different risk tertile are provided with differentiated management plan especially in terms of health education, follow-up frequency and treatment plan.
  • Behavioral: Strengthened health education — The education comprised 8 monthly sessions developed by GP and village doctors. At the 4th month, individual health counseling by village doctors will be done to encourage the imitation and maintenance of self-management behaviors, and to identify any potential problems in the program. It took half an hour per each participant. At the 8th month, self-management evaluation will be done to assess personal self-management ability. High risk participants are required to take the education course, and middle risk participants are only encouraging to take. All participants would receive the education messages twice a month, which introduce tips about the management of hypertension, diabetes and CVD risk factors.
  • Other: Financial incentives for integration of care — Specialists receive reimbursement for case discussion and high risk population management; GP receive reimbursement for providing education program and risk monitoring; Village doctor receive reimbursement for assisting education program, risk measurement and home visits. And overall services quality will be measured, and taken into account for annual performance evaluation.
  • Other: Supporting health information system — A dynamic patient risk monitoring information system is established for simplifying the risk data collection and entry for village doctors, meanwhile, GP and specialist can receive the updates of risk scores simultaneously. Apart from the function of risk monitoring, this system also incorporates the e-records of home visits, health education attendance as well as medical records including outpatient visits and hospitalizations. The upgraded information systems not only can support the healthcare professionals with comprehensive and real-time data, but also provide the performance evaluation data for policymakers.

Primary Outcomes

  • 10-year CVD risk score (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-20
Completion: 2025-12-20
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2560 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Contact Information
Study Contact:
Jin Prof. Xu, PhD
0086-82805701
xujin@hsc.pku.edu.cn
Xiaohong Xie
+86 13860506137
lilylwj@live.com
Shaxian County General Hospital
Pengfei Liu
+86 18177251898
lzxygb@126.com
Luzhai County People's hospital
Interventions
  • Other: Team-based care — The RISIMA model is provided by a family healthcare team composed of one village doctor, one general physician at township health centers and one specialist including cardiologists, neurologists or endocrinologists from county hospital. For villages without village doctor, public health professionals from township health centers would join the service team as the supplement. Within the team, three team members carry the different function. Village doctor is responsible for regular home visits, CVD risk measurement and organizing health education course. GP as the core service provider in the team is responsible for CVD risk monitoring, providing health education course for middle-high risk participants, and generating integrated care plans for each participant. Specialist is responsible for providing guidance particularly for high-risk population management to township and village doctors within the team.
  • Procedure: Risk-stratified care pathway — Based on WHO/ISH score, baseline population will be divided into three groups-low risk (10-year CVD risk: \&lt;10%), middle risk (10-year CVD risk: 10%\~20%) and high risk (10-year risk: \&gt;20%). With the support from experts and health care professionals, study had developed a risk-stratified care pathway on the basis of clinical guidance. According to the pathway, participants at different risk tertile are provided with differentiated management plan especially in terms of health education, follow-up frequency and treatment plan.
  • Behavioral: Strengthened health education — The education comprised 8 monthly sessions developed by GP and village doctors. At the 4th month, individual health counseling by village doctors will be done to encourage the imitation and maintenance of self-management behaviors, and to identify any potential problems in the program. It took half an hour per each participant. At the 8th month, self-management evaluation will be done to assess personal self-management ability. High risk participants are required to take the education course, and middle risk participants are only encouraging to take. All participants would receive the education messages twice a month, which introduce tips about the management of hypertension, diabetes and CVD risk factors.
  • Other: Financial incentives for integration of care — Specialists receive reimbursement for case discussion and high risk population management; GP receive reimbursement for providing education program and risk monitoring; Village doctor receive reimbursement for assisting education program, risk measurement and home visits. And overall services quality will be measured, and taken into account for annual performance evaluation.
  • Other: Supporting health information system — A dynamic patient risk monitoring information system is established for simplifying the risk data collection and entry for village doctors, meanwhile, GP and specialist can receive the updates of risk scores simultaneously. Apart from the function of risk monitoring, this system also incorporates the e-records of home visits, health education attendance as well as medical records including outpatient visits and hospitalizations. The upgraded information systems not only can support the healthcare professionals with comprehensive and real-time data, but also provide the performance evaluation data for policymakers.
Study Locations (3 sites)
Shaxian County General Hospital, Sanming, Fujian China
Luzhai County People's hospital, Liuzhou, Guangxi China
Luzhai County Traditional Medicine hospital, Liuzhou, China
Eligibility Criteria
Inclusion Criteria: 1. Aged between 40 and 70 years old; 2. Patients with hypertension or diabetes; 3. Permanent residents of the county where the research is conducted; 4. Already signed up with the family doctor team in the township where the research is located. Exclusion Criteria: 1. Unable to independently carry out the interventions required for the study; 2. Residing far from the village or township health center where the research is located, making it difficult to cooperate with visits; 3. Patients who refuse to participate; 4. Patients with comorbidities such as cancer that may interfere with the study visits or intervention effects; 5. Pregnant or lactating women
Conditions HER2-negative Breast Cancer, Hormone-rec...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used for hormone receptor positive HER2 negative breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood sample collection

Primary Outcomes

  • DiviTum®TKa assay as an early predictor of primary treatment resistance (Every cycle (approximately 28 days) until disease progression up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-30
Completion: 2031-06-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Pooja Advani, MBBS, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Florida
Pooja Advani, MBBS, MD
Mayo Clinic in Florida
Interventions
  • Procedure: Biospecimen Collection — Undergo blood sample collection
Study Locations (1 sites)
Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States
Eligibility Criteria
Inclusion Criteria: * Pre- or post-menopausal HR+ metastatic breast cancer patients who are: * Group 1: scheduled to initiate 1st line combination therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) and an FDA-approved endocrine therapy for pre- or post-menopausal HR+ metastatic breast cancer (mBC). * Group 2: scheduled to initiate second or later lines of therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) with or without an FDA-approved endocrine therapy for pre- or post-menopausal HR+ mBC. * Group 3: currently receiving 1st line therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) and an FDA-approved endocrine therapy for pre- or post-menopausal HR+ mBC. * Group 4: scheduled to initiate, or are currently receiving, 1st or 2nd line therapy of an FDA approved endocrine therapy (single agent) for pre- or post-menopausal HR+ mBC. * Group 5: scheduled to initiate or are currently receiving 1st line therapy of an FDA-approved CDK4/6 inhibitor (ribociclib or abemaciclib) with an FDA approved endocrine therapy for stage 2 or stage 3 adjuvant HR+ BC NOTE: Patients that meet eligibility criteria for any of the above groups that are already enrolled in an ongoing clinical trial are eligible for co-enrollment to this observational study. Exclusion Criteria: * Treatment including investigational agent or therapies * Early breast cancer diagnosis * Male breast cancer * Currently receiving treatment for other active malignancy at time of registration * EXCEPTIONS: Nonmelanoma skin cancer or carcinoma-in-situ (e.g. of cervix, prostate) * Inability to give written informed consent
Conditions Breast Cancer Female, Cardiometabolic Sy...
Phase NA
Enrollment 56
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of postmenopausal oncological women vs postmenopausal untreated controls (CT); and 2) to analyze the impact of two different 8-week physical exercise supervised interventions: HIIT training vs strength training focused on muscle power, on both cardiovascular capacities in these populations.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: HIIT program (8 weeks) — Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
  • Behavioral: MPI program (8 weeks) — Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.

Primary Outcomes

  • Fat oxidation during incremental test (Preintervention (only this one in cross-sectional study) and Postintervention (8 weeks after))
  • Detrended Fluctuation Analysis (Preintervention and Postintervention (8 weeks after))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2028-12-31
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Valencia
Collaborators: Generalitat Valenciana
Principal Investigators:
  • Cristina Blasco Lafarga, Tenured Professor (PRINCIPAL_INVESTIGATOR) - University of Valencia
Contact Information
Study Contact:
Cristina Blasco Lafarga, Tenured Professor
64372
m.cristina.blasco@uv.es
Cristina Blasco Lafarga, PhD
64372
m.cristina.blasco@uv.es
Faculty of Physical Activity and Sport Sciences
Jordi Monferrer-Marín, Predoctoral student
Faculty of Physical Activity and Sport Sciences
Interventions
  • Behavioral: HIIT program (8 weeks) — Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
  • Behavioral: MPI program (8 weeks) — Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
Study Locations (1 sites)
Faculty of Physical Activity and Sport Sciences, Valencia, Valencia 46010 Spain
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed of relapse free-cancer (RFC) or patients not diagnosed of any cancer at least the last 15 years (CG) * Aged between 35 and 75 years * Diagnostic of breast cancer (i.e., including ductal carcinoma, invasive carcinoma, triple negative; RFC) or physiological menopause (CG) * Not participating in a nutritional/dietary intervention * Not being physically active (i.e., not to be participating in any physical exercise program in the last 3 months, or performing less than 600 metabolic equivalents (METS)/week of moderate-vigorous physical activity). * To be capable and willing to provide informed consent * Not to suffer from any specific condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise intervention (i.e., determined by the research staff). Exclusion Criteria: * Medical contraindication for being engaged in an exercise. * Additional surgery planned within the intervention * Consuming usually betablocker or any drugs alterning nervous system functioning * History of another primary invasive cancer (RFC) or suffer a serious chronic illness (CG) * To present any of the following cardiac conditions: (i) myocardial infarction or coronary revascularization procedure within prior 3 months, (ii) uncontrolled hypertension (i.e., systolic ≥180 mmHg or diastolic ≥100 mmHg), (iii) uncontrolled arrhythmias (iv) valvular disease clinically significant, (v) decompensated heart failure or (vi) to suffer from known aortic aneurysm.